Secondary analysis of 75 people with MS on CD19+ B-cell guided interval dosing of ocrelizumab (209 intervals): time to B-cell repopulation varied widely between people (20.6–72.1 weeks) but little within a person (median variation 5.6%, about 2 weeks).
Secondary analysisn = 75
Hogenboom et al. Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab